National Healthcare Security Administration / 国家医保局
The National Healthcare Security Administration / 国家医保局 appears in 130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 as the payer-side actor in China’s innovation-drug ecosystem. The source names reimbursement and medical-insurance payment as part of the industry structure because approval alone does not create broad patient access or commercial return.
156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 adds the Innovative Drug Commercial Insurance Catalog as a policy signal from the payer side. The episode emphasizes that this catalog differs from basic医保: it can guide commercial insurers, but actual coverage still depends on insurer adoption.
Connections
- Unmet Medical Need Demand Pull - patient demand becomes investable only when payment and access channels exist.
- Clinical Development Capability - trial evidence and real clinical benefit matter for reimbursement as well as approval.
- China Biotech Globalization - global commercial capability includes payer and market-access work, not only sales teams.
- Innovative Drug Commercial Insurance Catalog and Biotech BD Data Validation Phase - payment-policy and 2026 execution context.